Related Articles |
Efficiency and security profile of regadenoson myocardial perfusion imaging: first expertise in Greece.
Hell J Nucl Med. 2017 Sep-Dec;20(Three):232-236
Authors: Koutsikos J, Angelidis G, Zafeirakis A, Mamarelis I, Vogiatzis M, Ilia E, Lazaridis Okay, Demakopoulos N
Summary
OBJECTIVE: MPI can present worthwhile data within the investigation of sufferers with identified or suspected coronary artery illness. The stress part of the research may be carried out with regadenoson, which was accepted for scientific use in Greece in 2016. We investigated the efficiency and security profile of regadenoson MPI primarily based on our 7 months institutional expertise.
PATIENTS AND METHODS: We studied 96 consecutive sufferers (59 males, 37 females, imply age 70.35y.o, vary: 46-87y.o.) referred to our division for a clinically indicated MPI research with pharmacological stress. Eleven sufferers suffered from continual obstructive pulmonary illness. Sufferers underwent regadenoson stress check, mixed with each stress and relaxation imaging. Information on the signs and electrocardiographic modifications on account of regadenoson administration had been recorded. Signs had been graded as 1-mild: a symptom that didn’t misery the affected person, 2-moderate: a symptom that distressed the affected person but it surely was self-limiting, or Three-severe: a symptom that distressed the affected person requiring medical intervention.
RESULTS: Regadenoson-related signs had been reported in 56 sufferers and had been: dyspnea, discomfort, dizziness, chest ache, epigastric ache, neck ache, headache, flushing, nausea, heartburn, weak spot, and higher limbs numbness. The severity of signs was recorded as grade 1 in 30 sufferers, grade 2 in 25 sufferers, and grade Three in 1 affected person. Two or extra completely different signs had been reported in 28 sufferers. Ischemic electrocardiographic modifications and arrhythmias had been noticed in eight sufferers.
CONCLUSION: Our findings help beforehand printed information indicating the optimum security profile of regadenoson MPI, even within the group of sufferers affected by continual obstructive pulmonary illness.
PMID: 29177261 [PubMed – indexed for MEDLINE]